ArticleThe Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology2025
Prognostic Value of Long Non-Coding RNAs GUSB Pseudogene 11 in Colorectal Cancer and Its Regulatory Effect on Tumor Progression.
Article in The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aims: Colorectal cancer (CRC) is the third most common cancer, and its progression to advanced diagnosis leads to a dismal prognosis. The long non-coding RNA (lncRNA) GUSB Pseudogene 11 (GUSBP11) can act in a variety of cancers. Nevertheless, the potential mechanism of GUSBP11 in CRC has not been reported. The purpose of this study is to investigate the relationship between the role of GUSBP11 expression in CRC progression as well as prognosis. Materials and Methods: Two hundred and fifty-nine CRC patients were recruited. Expression levels of GUSBP11 and downstream target genes in CRC cell lines were evaluated by quantitative reverse transcription polymerase chain reaction. The influence of clinical characteristics and GUSBP11 on prognosis was evaluated by the proportional hazards model. Cell-Counting-Kit-8 and transwell assays were conducted for detection of CRC cell proliferation, migration, and invasion. Dual luciferase and correlation analyses were used to validate GUSBP11 with predicted genes. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses were performed to analyze downstream gene function and signaling pathways. Results: The expression of GUSBP11 was upregulated in CRC and relevant to the deterioration of prognosis. The CRC cell proliferation, migration, and invasion were inhibited by GUSBP11 silencing. miR-605-3p was the downstream target gene of GUSBP11, and its expression is negatively regulated by GUSBP11. Conclusion: Taken together, this study highlights that the inhibition of miR-605-3p by GUSBP11 to regulate the downstream signaling pathway leads to prognostic malignancy and promotes tumor growth in CRC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.